1. Scrip

US judge sets hearing for Biogen vs Elan dispute over Tysabri

 
• By Nancy Faigen

A federal judge has agreed to give Biogen Idec expedited discovery relating to documents concerning an ongoing dispute with Elan. Elan is fighting a claim from Biogen Idec that its recent $1.5 billion deal with Johnson & Johnson placed it in material breach of the commercialisation pact for the multiple sclerosis drug Tysabri (natalizumab). A hearing, originally set for the end of August, has been moved to September 10th.

A federal judge has agreed to give Biogen Idec expedited discovery relating to documents concerning an ongoing dispute with Elan. Elan is fighting a claim from Biogen Idec that its recent $1.5 billion deal with Johnson & Johnson placed it in material breach of the commercialisation pact for the multiple sclerosis drug Tysabri (natalizumab). A hearing, originally set for the end of August, has been moved to September 10th.

The case is before Judge Deborah Batts of the US District Court for the Southern District of New York. Elan had filed a complaint in the same court to prevent...

More from Neurological

More from Therapeutic Category

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.